<DOC>
	<DOCNO>NCT00206713</DOCNO>
	<brief_summary>The purpose study evaluate whether treatment Leukine patient Crohn 's disease previously respond Leukine help , relapse .</brief_summary>
	<brief_title>Efficacy Study Sargramostim Retreatment Patients Who Have Crohn 's Disease Who Have Previously Responded Treatment With Sargramostim</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>You must 18 year old . You must active Crohn 's disease time screen . You must 18 year old . You must active Crohn 's disease time screen . You must able give injection study drug another person help give injection . You must pregnant agree use birth control sexually active male female childbearing potential . You may pregnant breastfeeding . You may colostomy ileostomy . You may take prohibited medication . You may GI surgery bowel obstruction last 6 month . You may ever take drug drug similar type past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Crohn Disease</keyword>
</DOC>